Material Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

The consolidated financial statements of the Group (the "Consolidated Financial Statements") are presented as of December 31,

2025 and 2024, and for the years ended December 31, 2025, 2024 and 2023. The Consolidated Financial Statements have been

approved by the Directors on April 29, 2026, and are prepared in accordance with IFRS Accounting Standards as issued by the the

International Accounting Standards Board ("IASB").

For presentation of the Consolidated Statement of Comprehensive Income/(Loss), the Group uses a classification based on the

function of expenses, rather than based on their nature, as it is more representative of the format used for internal reporting and

management purposes and is consistent with international practice.

Certain amounts in the Consolidated Financial Statements and accompanying notes may not add due to rounding. All percentages

have been calculated using unrounded amounts.

Basis of Measurement

The Consolidated Financial Statements are prepared on the historical cost basis except that the following assets and liabilities are

stated at their fair value: investments held at fair value, investments in notes from associates and preferred share liabilities.

Use of Judgments and Estimates

In preparing the Consolidated Financial Statements, management has made judgments, estimates and assumptions that affect the

application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results

may differ from these estimates. Estimates and underlying assumptions are reviewed on an on-going basis.

Significant estimation is applied in determining the following:

—Financial instruments (see Note 19. Financial Instruments): In accordance with IFRS 9, Financial Instruments ("IFRS 9"), the Group

carries certain financial assets and financial liabilities at fair value, with changes in fair value through profit and loss ("FVTPL").

Valuation of the aforementioned financial instruments includes determining the appropriate valuation methodology and making

certain estimates such as the equity value of an entity and the probability of entering into an initial public offering.

Significant judgement is also applied in determining the following:

—Whether financial instruments should be classified as liability or equity (see Note 17. Subsidiary Preferred Shares). The judgement

includes an assessment of whether the financial instruments include contractual obligations of the Group to deliver cash or other

financial assets or to exchange financial assets or financial liabilities with another party, and whether those obligations could be

settled by the Group exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments.

Further information about these critical judgments and estimates is included below under Financial Instruments.

—Whether the power to control investees exists (see Note 5. Investments Held at Fair Value, Note 6. Investments in Associates and

Note 8. Gain/(loss) on Deconsolidation of Subsidiary and accounting policy with regard to Subsidiaries below). The judgement

includes an assessment of whether the Group has (i) power over the investee; (ii) exposure, or rights, to variable returns from its

involvement with the investee; and (iii) the ability to use its power over the investee to affect the amount of its own returns. The

Group considers among others its voting shares, shareholder agreements, ability to appoint board members, representation on

the board, rights to appoint management, de facto control, and investee dependence on the Group. If the power to control the

investee exists, it consolidates the financial statements of such investee in the Consolidated Financial Statements of the Group.

Upon issuance of new shares in an investee and/or a change in any shareholders or governance agreements, the Group

reassesses its ability to control the investee based on the revised voting interest, revised board composition and revised

subsidiary governance and management structure. When such new circumstances result in the Group losing its power to control

the investee, the investee is deconsolidated.

—Whether the Group has significant influence over financial and operating policies of investees in order to determine if the Group

should account for its investment as an associate based on IAS 28 Investments in Associates and Joint Ventures ("IAS 28") or a

financial instrument based on IFRS 9 (refer to Note 5. Investments Held at Fair Value and Note 6. Investments in Associates). This

judgement includes, among others, an assessment whether the Group has representation on the board of directors of the

investee, whether the Group participates in the policy making processes of the investee, whether there is any interchange of

managerial personnel, whether there is any essential technical information provided to the investee and if there are any

transactions between the Group and the investee.


1.	Material Accounting Policies continued

—Upon determining that the Group does have significant influence over the financial and operating policies of an investee, if the

Group holds more than a single instrument issued by its equity-accounted investee, judgement is required to determine whether

the additional instrument forms part of the investment in the associate, which is accounted for under IAS 28 and scoped out of

IFRS 9, or it is a separate financial instrument that falls in the scope of IFRS 9. This judgement includes an assessment of the

characteristics of the financial instrument of the investee held by the Group and whether such financial instrument provides

access to returns underlying an ownership interest.

—When the Group has other investments in an equity accounted investee that are not accounted for under IAS 28, judgement is

required in determining if such investments constitute long-term interests ("LTI") for the purposes of IAS 28. This determination is

based on the individual facts and circumstances and characteristics of each investment, but is driven, among other factors, by the

intention and likelihood to settle the instrument through redemption or repayment in the foreseeable future, and whether or not

the investment is likely to be converted to common stock or other equity instruments. After considering the individual facts and

circumstances of the Group’s investment in its associate's preferred stock in the manner described above, including the long-

term nature of such investment, the ability of the Group to convert its preferred stock investment to an investment in common

shares and the likelihood of such conversion, the Group concluded that such investment was considered a long-term interest.

—In determining the appropriate accounting treatment for the Royalty Purchase Agreement during 2023, management applied

significant judgement (refer to Note 18. Sale of Future Royalties Liability).

Going Concern

Considering

the Group’s financial position as of December 31, 2025, and its principal risks and opportunities, the Group prepared a going

concern analysis covering a period of at least the twelve-month period from the date of signing the Consolidated Financial

Statements ("the going concern period") utilizing realistic scenarios and applying a severe but plausible downside scenario. Even

under the downside scenario, the analysis demonstrates the Group continues to maintain sufficient liquidity headroom and

continues to comply with all financial obligations. The Board of Directors believe the Group and the Parent is adequately resourced

to continue in operational existence for at least the twelve-month period from the date of signing the Consolidated Financial

Statements. Accordingly, the Board of Directors considered it appropriate to adopt the going concern basis of accounting in

preparing the Consolidated Financial Statements and the PureTech Health plc Financial Statements.

Basis of consolidation

The Consolidated Financial Statements as of December 31, 2025 and 2024, and for each of the years ended December 31, 2025,

2024 and 2023, comprise PureTech Health plc and its consolidated subsidiaries. Intra-group balances and transactions, and any

unrealized income and expenses arising from intra-group transactions, are eliminated.

Subsidiaries and Change in Subsidiary Ownership and Loss of Control

Subsidiaries

As used in these financial statements, the term subsidiaries refers to entities that are controlled by the Group. Under applicable

accounting rules, the Group controls an entity when it is exposed to, or has the rights to, variable returns from its involvement with

the entity and has the ability to affect those returns through its power over the entity. In assessing control, the Group takes into

consideration potential voting rights, board representation, shareholders' agreements, ability to appoint board of directors and

management, de facto control and other related factors. The financial statements of subsidiaries are included in the Consolidated

Financial Statements from the date that control commences until the date that control ceases. Losses applicable to the non-

controlling interests ("NCI") in a subsidiary are allocated to the non-controlling interests even if doing so causes the non-controlling

interests to have a deficit balance.

A list of all current and former subsidiaries organized with respect to classification as of December 31, 2025, and the Group’s total

voting percentage, based on outstanding voting common and preferred shares as of December 31, 2025, 2024 and 2023, is outlined

below. All current subsidiaries are domiciled within the United States and conduct business activities solely within the United States.

Change in Subsidiary Ownership and Loss of Control

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

Where the Group loses control of a subsidiary, the assets and liabilities are derecognized along with any related non-controlling

interest. Any interest retained in the former subsidiary is measured at fair value when control is lost. Any resulting gain or loss is

recognized as profit or loss in the Consolidated Statement of Comprehensive Income/(Loss).

Associates

As used in the Consolidated Financial Statements, the term associates are those entities in which the Group has no control but

maintains significant influence over the financial and operating policies. Significant influence is presumed to exist when the Group

holds between 20 and 50 percent of the voting power of an entity, unless it can be clearly demonstrated that this is not the case. The

Group evaluates if it maintains significant influence over associates by assessing if the Group has the power to participate in the

financial and operating policy decisions of the associate.

Application of the Equity Method to Associates

Associates are accounted for using the equity method (equity accounted investees) and are initially recognized at cost, or if

recognized upon deconsolidation, they are initially recorded at fair value at the date of deconsolidation. The Consolidated Financial

Statements include the Group’s share of the total comprehensive income or loss of equity accounted investees, from the date that

significant influence commences until the date that significant influence ceases.

To the extent the Group holds interests in associates that are not providing access to returns underlying ownership interests, the

instrument is accounted for in accordance with IFRS 9 as investments held at fair value.

When the Group’s share of losses exceeds its equity method investment in the investee, losses are applied against long-term

interests, which are investments accounted for under IFRS 9. Investments are determined to be long-term interests when they are

long-term in nature and in substance they form part of the Group's net investment in that associate. This determination is impacted

by many factors, among others, whether settlement by the investee through redemption or repayment is planned or likely in the

foreseeable future, whether the investment can be converted and/or is likely to be converted to common stock or other equity

instrument and other factors regarding the nature of the investment. Whilst this assessment is dependent on many specific facts and

circumstances of each investment, typically conversion features whereby the investment is likely to convert to common stock or other

equity instruments would point to the investment being a long-term interest. Similarly, where the investment is not planned or likely

to be settled through redemption or repayment in the foreseeable future, this would indicate that the investment is a long-term

interest. When the net investment in the associate, which includes the Group’s investments in other long-term interests, is reduced

to nil, recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations

or made payments on behalf of an investee.

The Group has adopted the amendments to IAS 28 that addresses the dual application of IAS 28 and IFRS 9 when equity method

losses are applied against long-term interests. The amendments provide the annual sequence in which both standards are to be

applied in such a case. The Group has applied the equity method losses to the long-term interests presented as part of Investments

held at fair value subsequent to remeasuring such investments to their fair value at the balance sheet date.

Sale of Future Royalties Liability

The Group accounts for the sale of future royalties liability as a financial liability, as it continues to hold the rights under the royalty

bearing licensing agreement and has a contractual obligation to deliver cash to an investor for a portion of the royalty it receives.

Interest on the sale of future royalties liability is recognized using the effective interest rate over the life of the related royalty stream.

The sale of future royalties liability and the related interest expense are based on the Group’s current estimates of future royalties

expected to be paid over the life of the arrangement. Forecasts are updated periodically as new data is obtained. Any increases,

decreases or a shift in timing of estimated cash flows require the Group to re-calculate the amortized cost of the sale of future

royalties liability as the present value of the estimated future contractual cash flows that are discounted at the liability’s original

effective interest rate. The adjustment is recognized immediately in profit or loss as income or expense.

Financial Instruments

Classification

The Group classifies its financial assets in the following measurement categories:

—Those to be measured subsequently at fair value either through other comprehensive income "FVOCI", or through profit or loss

"FVTPL", and

—Those to be measured at amortized cost.

The classification depends on the Group’s business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses are recorded in profit or loss.

Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at FVTPL,

transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets that are

carried at FVTPL are expensed.

Impairment

The Group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized

cost. For trade receivables, the Group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses

to be recognized from initial recognition of the receivables.

Financial Assets

The Group’s financial assets consist of cash and cash equivalents, investments in debt securities, trade and other receivables,

investments in notes from associates, restricted cash deposits and investments in equity securities. The Group’s financial assets are

virtually all classified into the following categories: investments held at fair value, investments in notes from associates, trade and

other receivables, short-term investments and cash and cash equivalents. The Group determines the classification of financial assets

at initial recognition depending on the purpose for which the financial assets were acquired.


1.	Material Accounting Policies continued

Investments held at fair value are investments in equity instruments. Such investments consist of the Group's minority interest

holdings where the Group has no significant influence or preferred share investments that are not providing access to returns

underlying ownership interests and are categorized as debt instruments that are presented at fair value through profit and loss

because the amounts receivable do not represent solely payments of principal and interest. These financial assets are initially

measured at fair value and subsequently re-measured at fair value at each reporting date. The Group has elected to record the

changes in fair values for the financial assets falling under this category through profit and loss. Please refer to Note 5. Investments

Held at Fair Value.

Changes in the fair value of financial assets at FVTPL are recognized in other income/(expense) in the Consolidated Statement of

Comprehensive Income/(Loss) as applicable.

The investments in notes from associates, since their contractual terms do not consist solely of cash flow payments of principal and

interest on the principal amount outstanding, are initially and subsequently measured at fair value, with changes in fair value

recognized through profit and loss.

Cash and cash equivalents consist of demand deposits with banks and other financial institutions and highly liquid instruments with

original maturities of three months or less at the date of purchase. Cash and cash equivalents are carried at cost, which

approximates their fair value.

Short-term investments consist of short-term US treasury bills that are held to maturity. The contractual terms consist solely of

payment of the principal and interest and the Group's business model is to hold the treasury bills to maturity. As such, such short-

term investments are recorded at amortized cost. As of the balance sheet date, amortized cost approximated the fair value of such

short-term investments.

Trade and other receivables are non-derivative financial assets with fixed and determinable payments that are not quoted on active

markets. These financial assets are carried at the amounts expected to be received less any expected lifetime losses. Such losses are

determined taking into account previous experience, credit rating and economic stability of counterparty and economic conditions.

When a trade receivable is determined to be uncollectible, it is written off against the available provision. As of the balance sheet

date, the Group did not record any such expected lifetime losses related to the outstanding trade and other receivable balances.

Trade and other receivables are included in current assets, unless maturities are greater than 12 months after the end of the

reporting period.

Financial Liabilities

The Group’s financial liabilities primarily consist of trade and other payables, and preferred shares.

The majority of the Group’s subsidiaries have preferred shares and certain notes payable with embedded derivatives, which are

classified as current liabilities. When the Group has preferred shares and notes with embedded derivatives that qualify for

bifurcation, the Group has elected to account for the entire instrument as FVTPL after determining under IFRS 9 that the instrument

qualifies to be accounted for under such FVTPL method.

The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.

Equity Instruments Issued by the Group

Financial instruments issued by the Group are treated as equity only to the extent that they meet the following two conditions,

in accordance with IAS 32:

1They include no contractual obligations upon the Group to deliver cash or other financial assets or to exchange financial assets

or financial liabilities with another party under conditions that are potentially unfavorable to the Group; and

2Where the instrument will or may be settled in the Group’s own equity instruments, it is either a non-derivative that includes no

obligation to deliver a variable number of the Group’s own equity instruments or is a derivative that will be settled by the Group

exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments.

To the extent that this definition is not met, the financial instrument is classified as a financial liability. Where the instrument so

classified takes the legal form of the Group’s own shares, the amounts presented in the Group's shareholders' equity exclude

amounts in relation to those shares.

Changes in the fair value of liabilities at FVTPL are recognized in net finance income/(costs) in the Consolidated Statement of

Comprehensive Income/(Loss) as applicable.

IFRS 15, Revenue from Contracts with Customers

The standard establishes a five-step principle-based approach for revenue recognition and is based on the concept of recognizing

an amount that reflects the consideration for performance obligations only when they are satisfied, and the control of goods or

services is transferred.

The majority of the Group’s contract revenue is generated from licenses and services, some of which are part of collaboration

arrangements.

Management reviewed contracts where the Group received consideration in order to determine whether or not they should be

accounted for in accordance with IFRS 15. To date, the Group has entered into transactions that generate revenue and meet the

scope of either IFRS 15 or IAS 20 Accounting for Government Grants. Contract revenue is recognized at either a point-in-time or

over time, depending on the nature of the performance obligations.


1.	Material Accounting Policies continued

The Group accounts for agreements that meet the definition of IFRS 15 by applying the following five step model:

—Identify the contract(s) with a customer – A contract with a customer exists when (i) the Group enters into an enforceable contract

with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment

terms related to those goods or services, (ii) the contract has commercial substance and, (iii) the Group determines that collection

of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability

to pay the promised consideration.

—Identify the performance obligations in the contract – Performance obligations promised in a contract are identified based on the

goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can

benefit from the good or service either on its own or together with other resources that are readily available from third parties or

from the Group, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately

identifiable from other promises in the contract.

—Determine the transaction price – The transaction price is determined based on the consideration to which the Group will be

entitled in exchange for transferring goods or services to the customer. To the extent the transaction price includes variable

consideration, the Group estimates the amount of variable consideration that should be included in the transaction price utilizing

either the expected value method or the most likely amount method depending on the nature of the variable consideration.

Variable consideration is included in the transaction price if, in the Group’s judgement, it is probable that a significant future

reversal of cumulative revenue under the contract will not occur.

—Allocate the transaction price to the performance obligations in the contract – If the contract contains a single performance

obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple

performance obligations require an allocation of the transaction price to each performance obligation based on a relative

standalone selling price basis.

—Recognize revenue when (or as) the Group satisfies a performance obligation – The Group satisfies performance obligations

either over time or at a point in time as discussed in further detail below. Revenue is recognized at the time the related

performance obligation is satisfied by transferring a promised good or service to a customer.

Revenue generated from services agreements (typically where licenses and related services were combined into one performance

obligation) is determined to be recognized over time when it can be determined that the services meet one of the following: (a) the

customer simultaneously receives and consumes the benefits provided by the entity’s performance as the entity performs; (b) the

entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the entity’s

performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for

performance completed to date.

It was determined that the Group has contracts that meet criteria (a), since the customer simultaneously receives and consumes the

benefits provided by the Group’s performance as the Group performs. Therefore, revenue is recognized over time using the input

method based on costs incurred to date as compared to total contract costs. The Group believes that in research and development

service type agreements using costs incurred to date represents the most faithful depiction of the entity’s performance towards

complete satisfaction of a performance obligation.

Revenue from licenses that are not part of a combined performance obligation are recognized at a point in time. Such licenses relate

to intellectual property that has significant stand-alone functionality and as such represent a right to use the entity's intellectual

property as it exists at the point in time at which the license is granted.

Royalty revenue received in respect of licensing agreements when the license of intellectual property is the predominant item in the

arrangement is recognized as the related third-party sales in the licensee occur.

Amounts that are receivable or have been received per contractual terms but have not been recognized as revenue since

performance has not yet occurred or has not yet been completed are recorded as deferred revenue. The Group classifies as non-

current deferred revenue amounts received for which performance is expected to occur beyond one year or one operating cycle.

Grant Revenue

The Group recognizes grants from governmental agencies as grant revenue in the Consolidated Statement of Comprehensive

Income/(Loss), gross of the expenditures that were related to obtaining the grant, when there is reasonable assurance that the

Group will comply with the conditions within the grant agreement and there is reasonable assurance that payments under the grants

will be received. The Group evaluates the conditions of each grant as of each reporting date to ensure that the Group has

reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant payment will be

received as a result of meeting the necessary conditions.

The Group submits qualifying expenses for reimbursement after the Group has incurred the research and development expense.

The Group records an unbilled receivable upon incurring such expenses. In cases in which the grant revenue is received prior to the

expenses being incurred or recognized, the amounts received are deferred until the related expense is incurred and/or recognized.

Grant revenue is recognized in the Consolidated Statement of Comprehensive Income/(Loss) at the time in which the Group

recognizes the related reimbursable expense for which the grant is intended to compensate.

Functional and Presentation Currency

The Consolidated Financial Statements are presented in United States dollars (“US dollars”). The functional currency of all members

of the Group is the U.S. dollar. The Group's share in foreign exchange differences in associates were reported in other

comprehensive income/(loss).

Foreign Currency

Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate

ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are

retranslated to the functional currency at the foreign exchange rate ruling at that date. Foreign exchange differences arising on

remeasurement are recognized in the Consolidated Statement of Comprehensive Income/(Loss). Non-monetary assets and liabilities

that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

Share Capital

Ordinary shares are classified as equity. The Group's equity is comprised of share capital, share premium, merger reserve, other

reserve, translation reserve, and retained earnings/accumulated deficit.

Treasury Shares

Treasury shares acquired as a result of repurchasing shares are recognized at cost and are deducted from shareholders' equity.

No gain or loss is recognized in profit and loss for the purchase, sale, re-issue or cancellation of the Group's own equity shares.

The nominal value related to shares that are repurchased and cancelled are reduced from share capital and transferred to a capital

redemption reserve.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses. Cost includes

expenditures that are directly attributable to the acquisition of the asset. Assets under construction represent leasehold improvements

and machinery and equipment to be used in operations or research and development activities. When parts of an item of property and

equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment.

Depreciation is calculated using the straight-line method over the estimated useful life of the related asset:


Laboratory and manufacturing equipment	2-8 years
Furniture and fixtures	7 years
Computer equipment and software	1-5 years
Leasehold improvements	5-10 years, or the remaining term of the lease, if shorter

Depreciation methods, useful lives and residual values are reviewed at each balance sheet date.

Intangible Assets

Intangible assets, which include purchased patents and licenses with finite useful lives, are carried at historical cost less accumulated

amortization, if amortization has commenced. Intangible assets with finite lives are amortized from the time they are available for

their intended use. Amortization is calculated using the straight-line method to allocate the costs of patents and licenses over their

estimated useful lives.

Research and development intangible assets, which are still under development and have accordingly not yet obtained marketing

approval, are presented as In-Process Research and Development (IPR&D). The cost of IPR&D represents upfront payments as well

as additional contingent payments based on development, regulatory and sales milestones related to certain license agreement

where the Group licenses IP from a third party. These milestones are capitalized as the milestone is triggered. See Note 25.

Commitments and Contingencies. IPR&D is not amortized since it is not yet available for its intended use, but it is evaluated for

potential impairment on an annual basis or more frequently when facts and circumstances warrant.

Impairment of Non-Financial Assets

The Group reviews the carrying amounts of its property and equipment and intangible assets at each reporting date to determine

whether there are indicators of impairment. If any such indicators of impairment exist, then an asset’s recoverable amount is

estimated. The recoverable amount is the higher of an asset’s fair value less cost of disposal and value in use.

The Group’s IPR&D intangible assets are not yet available for their intended use. As such, they are tested for impairment at least annually.

An impairment loss is recognized when an asset’s carrying amount exceeds its recoverable amount. For the purposes of impairment

testing, assets are grouped at the lowest levels for which there are largely independent cash flows. If a non-financial asset instrument

is impaired, an impairment loss is recognized in the Consolidated Statement of Comprehensive Income/(Loss).

Investments in associates are considered impaired if, and only if, objective evidence indicates that one or more events, which

occurred after the initial recognition, have had an impact on the future cash flows from the net investment and that impact can be

reliably estimated. If an impairment exists, the Group measures an impairment by comparing the carrying value of the net

investment in the associate to its recoverable amount and recording any excess as an impairment loss.

Employee Benefits

Short-Term Employee Benefits

Short-term employee benefit obligations are measured on an undiscounted basis and expensed as the related service is provided.

A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation due to past

service provided by the employee, and the obligation can be estimated reliably.

Defined Contribution Plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity

and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are

recognized as an employee benefit expense in the periods during which related services are rendered by employees.

Share-based Payments

Share-based payment arrangements, in which the Group receives goods or services as consideration for its own equity instruments, are

accounted for as equity-settled share-based payment transactions (except certain restricted stock units – see below) in accordance with

IFRS 2. The grant date fair value of employee share-based payment awards is recognized as an expense with a corresponding increase

in equity over the requisite service period related to the awards. The amount recognized as an expense is adjusted to reflect the actual

number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount

ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance

conditions at the vesting date. For share-based payment awards with market conditions, the grant date fair value is measured to reflect

such conditions and there is no true-up for differences between expected and actual outcomes.

Certain restricted stock units are treated as liability settled awards as the Group has a historical practice of settling these awards in

cash. Such awards are remeasured at every reporting date until settlement date and are recognized as compensation expense over

the requisite service period. Differences in remeasurement are recognized in profit and loss. The cumulative cost that will ultimately

be recognized in respect of these awards will equal to the amount at settlement.

The fair value of the awards is measured using option pricing models and other appropriate models, which take into account the

terms and conditions of the awards granted.

Development Costs

Expenditures on research activities are recognized as incurred in the Consolidated Statement of Comprehensive Income/(Loss). In

accordance with IAS 38, development costs are capitalized only if the expenditure can be measured reliably, the product or process is

technically and commercially feasible, future economic benefits are probable, the Group can demonstrate its ability to use or sell the

intangible asset, the Group intends to and has sufficient resources to complete development and to use or sell the asset, and it is able to

measure reliably the expenditure attributable to the intangible asset during its development. The point at which technical feasibility is

determined to have been reached is, generally, when regulatory approval has been received where applicable. Management determines

that commercial viability has been reached when a clear market and pricing point have been identified, which may coincide with

achieving meaningful recurring sales. Otherwise, the development expenditure is recognized as incurred in the Consolidated Statement

of Comprehensive Income/(Loss). As of the balance sheet date, the Group has not capitalized any development costs.

Provisions

A provision is recognized in the Consolidated Statement of Financial Position when the Group has a present legal or constructive

obligation due to a past event that can be reliably measured, and it is probable that an outflow of economic benefits will be

required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that

reflects risks specific to the liability.

Leases

The Group’s leases are virtually all leases of real estate for use in operations. The Group includes options that are reasonably certain to

be exercised as part of the determination of the lease term. The group determines if an arrangement is a lease at inception of the

contract in accordance with guidance detailed in IFRS 16. Right-of-use ("ROU") assets represent the Group’s right to use an underlying

asset for the lease term and lease liabilities represent the Group's obligation to make lease payments arising from the lease. Operating

lease ROU assets and lease liabilities are recognized at commencement date based on the present value of the lease payments over

the lease term. As most of the Group's leases do not provide an implicit rate, the Group used its estimated incremental borrowing rate,

based on information available at commencement date, in determining the present value of future payments.

The Group has elected to account for lease payments as an expense on a straight-line basis over the life of the lease for:

—Leases with a term of 12 months or less and containing no purchase options; and

—Leases where the underlying asset has a value of less than $5,000.

The right-of-use asset is depreciated on a straight-line basis and the related lease liability gives rise to an interest charge.

Finance Income and Finance Costs

Finance income consists of interest income on funds invested in money market funds and U.S. treasuries. Finance income is

recognized as it is earned. Finance costs consist mainly of loan, notes and lease liability interest expenses, interest expense due to

accretion of and adjustment to sale of future royalties liability as well as the changes in the fair value of financial liabilities carried at

FVTPL (such changes can consist of finance income when the fair value of such financial liabilities decrease).

Taxation

Tax on the profit or loss for the year comprises current and deferred income tax. In accordance with IAS 12, tax is recognized in the

Consolidated Statement of Comprehensive Income/(Loss) except to the extent that it relates to items recognized directly in equity.

Current income tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or

substantially enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized due to temporary differences between the carrying amounts of assets and liabilities for financial reporting

purposes and the amounts used for taxation purposes. Deferred tax assets are recognized for unused tax losses, unused tax credits

and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they

can be used. Deferred tax assets with respect to investments in associates are recognized only to the extent that it is probable the

temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference

can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable

that the related tax benefit will be realized.


1.	Material Accounting Policies continued

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax

rates enacted or substantively enacted at the reporting date.

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current

tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on

either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

Fair Value Measurements

The Group’s accounting policies require that certain financial assets and certain financial liabilities be measured at their fair value.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure

fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. Fair values are

categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

—Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

—Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly

(i.e. as prices) or indirectly (i.e. derived from prices).

—Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change

has occurred.

The carrying amount of cash and cash equivalents, accounts receivable, restricted cash, deposits, accounts payable, accrued

expenses and other current liabilities in the Group’s Consolidated Statement of Financial Position approximates their fair value

because of the short maturities of these instruments.

Operating Segments

Operating segments are reported in a manner that is consistent with the internal reporting provided to the chief operating decision

maker (“CODM”). The CODM reviews discrete financial information for the operating segments in order to assess their performance

and is responsible for making decisions about resources allocated to the segments. The CODM has been identified as the Group’s

Board of Directors.